Business
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need by giving providers a new, innovative option that offers patients greater choice, independence and flexibility – REDWOOD CITY, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States. UDENYCA® is a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.1 UDENYCA® AI’s streamlined design offers a simple option for in-office and at-home settings of care that administers pegfilgrastim in less than 10 seconds.2 “Those independent patients, with families and busy lifestyles, or those who just have a hard time coming back to the office the day after chemotherapy—that’s who is really going to benefit from the introduction of the UDENYCA® autoinjector,” said Francis Arena, M.D., Medical Director, NYU Langone Arena Oncology. \"This gives us more choice in meeting our patients’ needs, and the simple administration gives confidence in at-home administration.” “Patients have indicated in market research that quick administration, ease of use, and a sense of control and independence were the features and benefits of the autoinjector most important in their decision-making when choosing an at-home administration option. With UDENYCA AI, providers now have a new option that offers their patients where and how to receive their therapy, and health plans have a new option to increase access for patients,” said Paul Reider, Chief Commercial Officer of Coherus. “Our goal is to be the only pegfilgrastim product offering value across three differentiated presentations, fully meeting market needs and creating a durable franchise positioned to maximize market share growth. UDENYCA® AI represents substantial progress in that direction, and UDENYCA® will become the only pegfilgrastim product with three presentation options with the launch of our proprietary on-body injector later this year, if approved.” “Innovating to address patient needs is core to our mission...